Benjamin J. Zeskind - Feb 15, 2023 Form 4 Insider Report for Immuneering Corp (IMRX)

Role
PRESIDENT AND CEO, Director, 10%+ Owner
Signature
/s/ Michael D. Bookman, Attorney-in-Fact for Benjamin J. Zeskind
Stock symbol
IMRX
Transactions as of
Feb 15, 2023
Transactions value $
$0
Form type
4
Date filed
2/17/2023, 03:16 PM
Previous filing
Dec 27, 2022
Next filing
Feb 9, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IMRX Stock Option Award $0 +352K $0.00 352K Feb 15, 2023 Class A Common Stock 352K $4.25 Direct F1
transaction IMRX Stock Option Award $0 +21.8K +6.18% $0.00 374K Feb 15, 2023 Class A Common Stock 21.8K $4.68 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vests and becomes exercisable in equal monthly installments over a four-year period commencing on February 1, 2023, and will be fully vested and exercisable on January 1, 2027.
F2 The option vests and becomes exercisable in equal monthly installments over a four-year period commencing on February 1, 2023, and will be fully vested and exercisable on January 1, 2027.